Granules Hyderabad plant successfully closes USFDA inspection
New Delhi : Pharma firm Granules India said its Gagillapur facility in Hyderabad has completed USFDA inspection without any observations.
"The company's Gagillapur facility located in Hyderabad, Telangana has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing.
"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)."
The stock of Granules India was trading 2.29 per cent higher at Rs 122.75 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd